肝素辅因子II是一种新型的保护因子,可以在老年人中预防动脉动脉样硬化
Ken-ichi Aihara1, Hiroyuki Azuma, Nobuyuki Takamori
1Department of Medicine and Bioregulatory Sciences, University of Tokushima, Graduate School of Medicine, Kuramoto-cho Tokushima, Japan.
Circulation
|May 19, 2004
概括
肝素辅因子II (HCII) 的活性可以预防动脉样硬化. 较高的HCII水平与心血管斑块厚度的降低相关,这表明它在老年人中是一个比HDL胆固醇更强的抗动脉形成因子.
科学领域:
- 心血管研究研究心血管研究
- 生物化学 生物化学
- 老年学是指老年学的学科.
背景情况:
- 血凝素是动脉动脉栓塞的关键.
- 肝素辅因子II (HCII) 在动脉损伤部位抑制血栓.
- HCII可能调节血管血栓活性.
研究的目的:
- 研究血HCII活性作为对动脉样硬化的预防因素.
- 评估HCII在已有血管损伤的老年人中的作用.
主要方法:
- 超声波测量了306名日本老年人的动脉最大斑块厚度 (MPT).
- 统计分析评估了心血管风险因素,包括血HCII活性,与MPT对比.
- 回归分析确定了MPT的独立预测因素.
主要成果:
- 血HCII活性随着年龄的增长而下降.
- 脂蛋白 (a),HbA1c和糖尿病增加了MPT.
- 高密度脂蛋白 (HDL) 胆固醇和HCII活性与MPT负相关.
- HCII活动和高密度胆固醇独立抑制MPT,HCII是一个更强的因素.
结论:
- HCII是一种新且独立的抗动脉质因子.
- 在老年人中,HCII比HDL胆固醇更强有力的预测剂,可以预防心血管动脉样硬化.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Coronary Artery Disease II: Pathophysiology
1.1K
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K
Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
Venous Thrombosis III: Interprofessional Care
482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482


